Cagrilintide — long-acting amylin analog for satiety
In short
Modified amylin analog studied in clinical models of metabolic regulation and body weight control.
Overview
Cagrilintide (AM833) is a novel long-acting lipidated amylin analog that acts as a dual amylin and calcitonin receptor agonist. Developed for weight management and type 2 diabetes treatment, it shows superior weight loss potential when combined with semaglutide (CagriSema), with recent Phase 3 trials demonstrating up to 22.7% weight reduction.
Subcutaneous injection provides optimal bioavailability of lipidated amylin analog, targeting dual amylin and calcitonin receptors for satiety and metabolic effects
Molecular information
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
Enebo et al. (Lancet 2021, n=92) - CagriSema 2.4+2.4 mg/week for 20 weeks gave 17.1% reduction vs 9.8% for semaglutide alone.
Най-честите странични ефекти са стомашно-чревни през първите седмици. Те включват гадене, повръщане и диария. Антитела срещу cagrilintide се развиват при 46-73% от пациентите, но не влияят на ефикасността. Не се наблюдава клинично значимо удължаване на QT интервала в специализирани проучвания. Само 57.3% от пациентите достигат максималната доза от 2.4 мг в проучването REDEFINE 1. Формулата изисква киселинно pH (3.5-4.5) за предотвратяване на образуването на фибрили и деамидиране. Проверявайте разтворените течности за мътност или частици преди всяка употреба. Спрете употребата при тежко гадене или повръщане, което пречи на хидратацията. Прекратете при признаци на панкреатит като силна болка в корема, излъчваща се към гърба. Потърсете медицинска помощ при тежки алергични реакции или анафилаксия. Спрете при значителни реакции на мястото на инжектиране или образуване на абсцес. Изхвърлете незабавно при мътна течност, видими частици или гелообразна текстура, които показват образуване на фибрили.
3 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
CagriSema Phase 2
Phase 2 | 2.4 mg s.c. weekly | 20 weeks | 17.1% weight loss (combo)
Lancet · 2021
View the studyInformation about Cagrilintide is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadNo comments yet. Be the first.
Comments are reviewed before publishing.
